Labroots invites you to the 4th Annual Event in the CRISPR Virtual Event Series! This event will continue the conversation of the abilities of CRISPR-based editing, next-gen editing tools, precision ...
Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...
- More than 70 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; enrollment complete and regulatory submissions planned for late 2022- -Initiated and began dosing ...
We recently compiled a list of the 10 Best Stocks to Buy and Hold For 5 Years According to Cathie Wood. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) ...
If you're looking to add some growth to your portfolio, you may find it in biotech stocks. Two in particular offer investors a terrific opportunity right now. That's because both of them are in the ...
The gene-editing technique known as CRISPR is promising to revolutionize medicine. Some researchers are trying to help make it available for people with very rare genetic disorders. A gene-editing ...
Nobel Prize winner Emmanuelle Charpentier, Ph.D., and two universities have officially appealed in a dispute over certain patents for CRISPR gene editing, a long-running challenge that could have wide ...
Five years on from being the first person in the world to receive intravenous CRISPR treatment, Westmeath woman describes the clinical trial she participated in as ‘life-changing’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback